Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study.

Noe MH, Wan MT, Shin DB, Armstrong AW, Duffin KC, Chiesa Fuxench ZC, Kalb RE, Menter A, Simpson EL, Takeshita J, Tyring SK, Van Voorhees AS, Mehta NN, Gelfand JM.

J Am Acad Dermatol. 2019 Jun 1. pii: S0190-9622(19)30884-9. doi: 10.1016/j.jaad.2019.05.080. [Epub ahead of print]

PMID:
31163241
2.

Peripheral Retinal Vascular Leakage in Moderate to Severe Psoriasis: A Pilot Study.

Enos CW, Kapoor KG, Wagner AL, Van Voorhees AS.

J Am Acad Dermatol. 2019 May 28. pii: S0190-9622(19)30871-0. doi: 10.1016/j.jaad.2019.05.067. [Epub ahead of print] No abstract available.

PMID:
31150713
3.

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J.

Arthritis Care Res (Hoboken). 2019 Jan;71(1):2-29. doi: 10.1002/acr.23789. Epub 2018 Nov 30.

PMID:
30499259
4.

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J.

Arthritis Rheumatol. 2019 Jan;71(1):5-32. doi: 10.1002/art.40726. Epub 2018 Nov 30.

PMID:
30499246
5.

Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review.

Ford AR, Siegel M, Bagel J, Cordoro KM, Garg A, Gottlieb A, Green LJ, Gudjonsson JE, Koo J, Lebwohl M, Liao W, Mandelin AM 2nd, Markenson JA, Mehta N, Merola JF, Prussick R, Ryan C, Schwartzman S, Siegel EL, Van Voorhees AS, Wu JJ, Armstrong AW.

JAMA Dermatol. 2018 Aug 1;154(8):934-950. doi: 10.1001/jamadermatol.2018.1412.

PMID:
29926091
6.

Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial.

Mehta NN, Shin DB, Joshi AA, Dey AK, Armstrong AW, Duffin KC, Fuxench ZC, Harrington CL, Hubbard RA, Kalb RE, Menter A, Rader DJ, Reilly MP, Simpson EL, Takeshita J, Torigian DA, Werner TJ, Troxel AB, Tyring SK, Vanderbeek SB, Van Voorhees AS, Playford MP, Ahlman MA, Alavi A, Gelfand JM.

Circ Cardiovasc Imaging. 2018 Jun;11(6):e007394. doi: 10.1161/CIRCIMAGING.117.007394.

7.

Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.

Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, Merola JF, Ryan C, Siegel MP, Weinberg JM, Wu JJ, Van Voorhees AS.

J Am Acad Dermatol. 2018 Feb;78(2):383-394. doi: 10.1016/j.jaad.2017.06.043. Review.

PMID:
29332708
8.

Diversity in Dermatology Residency Programs.

Van Voorhees AS, Enos CW.

J Investig Dermatol Symp Proc. 2017 Oct;18(2):S46-S49. doi: 10.1016/j.jisp.2017.07.001. Review.

9.

Psoriasis in solid organ transplant patients: best practice recommendations from The Medical Board of the National Psoriasis Foundation.

Prussick R, Wu JJ, Armstrong AW, Siegel MP, Van Voorhees AS.

J Dermatolog Treat. 2018 Jun;29(4):329-333. doi: 10.1080/09546634.2017.1373737. Epub 2017 Oct 24.

PMID:
28884635
10.

Treatment of Inverse/Intertriginous Psoriasis: Updated Guidelines from the Medical Board of the National Psoriasis Foundation.

Khosravi H, Siegel MP, Van Voorhees AS, Merola JF.

J Drugs Dermatol. 2017 Aug 1;16(8):760-766.

PMID:
28809991
11.

Pediatric Psoriasis Comorbidity Screening Guidelines.

Osier E, Wang AS, Tollefson MM, Cordoro KM, Daniels SR, Eichenfield A, Gelfand JM, Gottlieb AB, Kimball AB, Lebwohl M, Mehta NN, Paller AS, Schwimmer JB, Styne DM, Van Voorhees AS, Tom WL, Eichenfield LF.

JAMA Dermatol. 2017 Jul 1;153(7):698-704. doi: 10.1001/jamadermatol.2017.0499.

12.

Psoriasis and comorbid diseases: Implications for management.

Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM.

J Am Acad Dermatol. 2017 Mar;76(3):393-403. doi: 10.1016/j.jaad.2016.07.065. Review.

13.

Psoriasis and comorbid diseases: Epidemiology.

Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM.

J Am Acad Dermatol. 2017 Mar;76(3):377-390. doi: 10.1016/j.jaad.2016.07.064. Review.

14.

From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis.

Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, Callis Duffin K, Eichenfield LF, Garg A, Gelfand JM, Gottlieb AB, Koo JY, Korman NJ, Krueger GG, Lebwohl MG, Leonardi CL, Mandelin AM, Menter MA, Merola JF, Pariser DM, Prussick RB, Ryan C, Shah KN, Weinberg JM, Williams MO, Wu JJ, Yamauchi PS, Van Voorhees AS.

J Am Acad Dermatol. 2017 Feb;76(2):290-298. doi: 10.1016/j.jaad.2016.10.017. Epub 2016 Nov 28. Review.

15.

From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis.

Choi YM, Debbaneh M, Weinberg JM, Yamauchi PS, Van Voorhees AS, Armstrong AW, Siegel M, Wu JJ.

J Am Acad Dermatol. 2016 Oct;75(4):798-805.e7. doi: 10.1016/j.jaad.2016.06.014. Epub 2016 Jul 25. Review.

PMID:
27461230
16.

Severe Small-Vessel Vasculitis Temporally Associated With Administration of Ustekinumab.

MacArthur KM, Merkel PA, Van Voorhees AS, Nguyen J, Rosenbach M.

J Drugs Dermatol. 2016 Mar;15(3):359-62.

PMID:
26954323
17.
18.

Validity of the Simple-Measure for Assessing Psoriasis Activity (S-MAPA) for objectively evaluating disease severity in patients with plaque psoriasis.

Chiesa Fuxench ZC, Callis Duffin K, Siegel M, Van Voorhees AS, Gelfand JM.

J Am Acad Dermatol. 2015 Nov;73(5):868-70. doi: 10.1016/j.jaad.2015.07.001. No abstract available.

19.

Annual screening for tuberculosis in patients on TNF-alfa antagonists.

Doherty SD, Lebwohl MG, Van Voorhees AS, Korman NJ, Hsu S.

J Am Acad Dermatol. 2015 Sep;73(3):e123. doi: 10.1016/j.jaad.2015.04.071. No abstract available.

PMID:
26282816
20.

Phototherapy in dermatology: A call for action.

Lim HW, Silpa-archa N, Amadi U, Menter A, Van Voorhees AS, Lebwohl M.

J Am Acad Dermatol. 2015 Jun;72(6):1078-80. doi: 10.1016/j.jaad.2015.03.017. Review.

PMID:
25981004
21.

Reply to: "Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors".

Doherty SD, Van Voorhees AS, Lebwohl MG, Korman NJ, Hsu S.

J Am Acad Dermatol. 2015 Apr;72(4):744. doi: 10.1016/j.jaad.2014.08.056. No abstract available.

PMID:
25773422
22.

Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.

Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.

JAMA Dermatol. 2015 Apr;151(4):432-8. doi: 10.1001/jamadermatol.2014.3456. Review.

PMID:
25517130
23.

Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation.

Crowley JJ, Weinberg JM, Wu JJ, Robertson AD, Van Voorhees AS; National Psoriasis Foundation.

JAMA Dermatol. 2015 Jan;151(1):87-94. doi: 10.1001/jamadermatol.2014.2983.

PMID:
25471223
24.

Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting.

Takeshita J, Wang S, Shin DB, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Stierstorfer MB, Brod BA, Schleicher SM, Robertson AD, Linn KA, Shinohara RT, Troxel AB, Van Voorhees AS, Gelfand JM.

J Am Acad Dermatol. 2014 Dec;71(6):1167-75. doi: 10.1016/j.jaad.2014.08.003. Epub 2014 Sep 24.

25.

Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting.

Takeshita J, Callis Duffin K, Shin DB, Krueger GG, Robertson AD, Troxel AB, Van Voorhees AS, Gelfand JM.

J Am Acad Dermatol. 2014 Oct;71(4):633-41. doi: 10.1016/j.jaad.2014.05.001. Epub 2014 Jun 11.

26.

Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis.

Chung J, Callis Duffin K, Takeshita J, Shin DB, Krueger GG, Robertson AD, Troxel AB, Van Voorhees AS, Edson-Heredia E, Gelfand JM.

J Am Acad Dermatol. 2014 Oct;71(4):623-32. doi: 10.1016/j.jaad.2014.04.063. Epub 2014 Jun 2.

27.

Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice.

Duffin KC, Yeung H, Takeshita J, Krueger GG, Robertson AD, Troxel AB, Shin DB, Van Voorhees AS, Gelfand JM.

Br J Dermatol. 2014 Mar;170(3):672-680. doi: 10.1111/bjd.12745.

28.

From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis.

Motaparthi K, Stanisic V, Van Voorhees AS, Lebwohl MG, Hsu S; Medical Board of the National Psoriasis Foundation.

J Am Acad Dermatol. 2014 Jan;70(1):178-86. doi: 10.1016/j.jaad.2013.08.049. Epub 2013 Nov 9.

PMID:
24220724
29.

From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.

Hugh J, Van Voorhees AS, Nijhawan RI, Bagel J, Lebwohl M, Blauvelt A, Hsu S, Weinberg JM.

J Am Acad Dermatol. 2014 Jan;70(1):168-77. doi: 10.1016/j.jaad.2013.09.020. Epub 2013 Nov 1. Review.

PMID:
24184141
30.

Research gaps in psoriasis: opportunities for future studies.

Ryan C, Korman NJ, Gelfand JM, Lim HW, Elmets CA, Feldman SR, Gottlieb AB, Koo JY, Lebwohl M, Leonardi CL, Van Voorhees AS, Bhushan R, Menter A.

J Am Acad Dermatol. 2014 Jan;70(1):146-67. doi: 10.1016/j.jaad.2013.08.042. Epub 2013 Oct 11. Review.

PMID:
24126079
31.

From the Medical Board of the National Psoriasis Foundation: Vaccination in adult patients on systemic therapy for psoriasis.

Wine-Lee L, Keller SC, Wilck MB, Gluckman SJ, Van Voorhees AS.

J Am Acad Dermatol. 2013 Dec;69(6):1003-13. doi: 10.1016/j.jaad.2013.06.046. Epub 2013 Sep 26. Review.

PMID:
24075223
32.

Using Hawthorne effects to improve adherence in clinical practice: lessons from clinical trials--reply.

Gelfand JM, Wang S, Takeshita J, Robertson AD, Krueger GG, Callis Duffin K, Van Voorhees AS.

JAMA Dermatol. 2013 Apr;149(4):491. doi: 10.1001/jamadermatol.2013.2846. No abstract available.

33.

TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation.

Kim BS, Siracusa MC, Saenz SA, Noti M, Monticelli LA, Sonnenberg GF, Hepworth MR, Van Voorhees AS, Comeau MR, Artis D.

Sci Transl Med. 2013 Jan 30;5(170):170ra16. doi: 10.1126/scitranslmed.3005374.

34.

Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity.

Martin ML, McCarrier KP, Chiou CF, Gordon K, Kimball AB, Van Voorhees AS, Gottlieb AB, Huang X, Globe D, Chau D, Viswanathan HN, Kricorian G.

J Dermatolog Treat. 2013 Aug;24(4):255-60. doi: 10.3109/09546634.2012.759639. Epub 2013 Jun 20.

PMID:
23249143
35.

Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis.

Abuabara K, Wan J, Troxel AB, Shin DB, Van Voorhees AS, Bebo BF Jr, Krueger GG, Callis Duffin K, Gelfand JM.

J Am Acad Dermatol. 2013 Feb;68(2):262-9. doi: 10.1016/j.jaad.2012.07.007. Epub 2012 Aug 19.

36.

Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.

Yeung H, Wan J, Van Voorhees AS, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Brod BA, Schleicher SM, Bebo BF Jr, Shin DB, Troxel AB, Gelfand JM.

J Am Acad Dermatol. 2013 Jan;68(1):64-72. doi: 10.1016/j.jaad.2012.06.035. Epub 2012 Jul 28.

37.

Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation.

Robinson A, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF Jr, Kalb RE.

J Am Acad Dermatol. 2012 Aug;67(2):279-88. doi: 10.1016/j.jaad.2011.01.032. Epub 2012 May 18.

PMID:
22609220
38.

Dermatologist preferences for treatments to compare in future randomized controlled comparative effectiveness trials for moderate to severe psoriasis.

Wan J, Abuabara K, Troxel AB, Shin DB, Van Voorhees AS, Bebo BF Jr, Krueger GG, Callis Duffin K, Gelfand JM.

Arch Dermatol. 2012 Apr;148(4):539-41. doi: 10.1001/archdermatol.2011.1399. No abstract available.

39.

Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting.

Gelfand JM, Wan J, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Stierstorfer MB, Brod BA, Schleicher SM, Bebo BF Jr, Troxel AB, Shin DB, Steinemann JM, Goldfarb J, Yeung H, Van Voorhees AS.

Arch Dermatol. 2012 Apr;148(4):487-94. doi: 10.1001/archdermatol.2012.370.

40.

Consensus guidelines for the management of plaque psoriasis.

Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF Jr; National Psoriasis Foundation Medical Board.

Arch Dermatol. 2012 Jan;148(1):95-102. doi: 10.1001/archdermatol.2011.1410.

PMID:
22250239
41.

Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation.

Bae YS, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo B Jr, Kimball AB; National Psoriasis Foundation.

J Am Acad Dermatol. 2012 Sep;67(3):459-77. doi: 10.1016/j.jaad.2011.07.039. Epub 2011 Oct 22. Review.

PMID:
22018758
42.

Treatment of refractory tumor necrosis factor inhibitor-induced palmoplantar pustulosis: a report of 2 cases.

Chu DH, Van Voorhees AS, Rosenbach M.

Arch Dermatol. 2011 Oct;147(10):1228-30. doi: 10.1001/archdermatol.2011.275. No abstract available.

PMID:
22006150
43.

Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients.

Wan J, Abuabara K, Troxel AB, Shin DB, Van Voorhees AS, Bebo BF Jr, Krueger GG, Callis Duffin K, Gelfand JM.

J Am Acad Dermatol. 2012 Mar;66(3):376-86. doi: 10.1016/j.jaad.2011.03.012. Epub 2011 Aug 19.

44.

Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study.

Mehta NN, Yu Y, Saboury B, Foroughi N, Krishnamoorthy P, Raper A, Baer A, Antigua J, Van Voorhees AS, Torigian DA, Alavi A, Gelfand JM.

Arch Dermatol. 2011 Sep;147(9):1031-9. doi: 10.1001/archdermatol.2011.119. Epub 2011 May 16.

45.

Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation.

Grozdev IS, Van Voorhees AS, Gottlieb AB, Hsu S, Lebwohl MG, Bebo BF Jr, Korman NJ; National Psoriasis Foundation.

J Am Acad Dermatol. 2011 Sep;65(3):537-545. doi: 10.1016/j.jaad.2010.05.014. Epub 2011 Apr 15.

PMID:
21496950
46.

In response to "Treatment of psoriasis with cyclosporine in patients with hepatitis C infection: risk or opportunity?".

Frankel A, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl M, Bebo BF Jr, Gottlieb A.

J Am Acad Dermatol. 2011 Apr;64(4):788-90. doi: 10.1016/j.jaad.2010.10.033. No abstract available.

PMID:
21414501
47.

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.

American Academy of Dermatology Work Group, Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Leonardi CL, Lim HW, Van Voorhees AS, Beutner KR, Ryan C, Bhushan R.

J Am Acad Dermatol. 2011 Jul;65(1):137-74. doi: 10.1016/j.jaad.2010.11.055. Epub 2011 Feb 8. Review.

PMID:
21306785
48.

Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation.

Bremmer S, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF Jr, Blauvelt A; National Psoriasis Foundation.

J Am Acad Dermatol. 2010 Dec;63(6):1058-69. doi: 10.1016/j.jaad.2009.09.053. Epub 2010 Aug 7. Review.

PMID:
20692722
49.

Potentially modifiable risk factors for adverse pregnancy outcomes in women with psoriasis.

Bandoli G, Johnson DL, Jones KL, Lopez Jiminez J, Salas E, Mirrasoul N, Van Voorhees AS, Chambers CD.

Br J Dermatol. 2010 Aug;163(2):334-9. doi: 10.1111/j.1365-2133.2010.09899.x. Epub 2010 Jun 9.

PMID:
20545678
50.

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy.

Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R.

J Am Acad Dermatol. 2010 Jan;62(1):114-35. doi: 10.1016/j.jaad.2009.08.026. Epub 2009 Oct 7. Review.

PMID:
19811850

Supplemental Content

Loading ...
Support Center